June 02, 2023
More than three dozen state-level enforcers reached a $102.5 million deal on Friday with Indivior Inc. to resolve claims that the drugmaker monopolized the market for the opioid addiction treatment Suboxone ahead of a looming September trial.
October 17, 2017
A month after a Pennsylvania federal judge refused to throw out antitrust claims brought by more than 40 states accusing U.K.-based Indivior Inc. of delaying the introduction of generics of its opioid addiction treatment Suboxone, he let its former sister company Reckitt Benckiser Healthcare escape the litigation Tuesday.
September 08, 2017
A Pennsylvania federal judge on Friday refused to dismiss a case brought by more than 40 states in multidistrict litigation accusing a U.K.-based drugmaker of delaying the introduction of generics of its opioid addiction treatment Suboxone, ruling that at the current stage in the case, the states have properly alleged their claims.
February 22, 2017
Indivior Inc. asked a Pennsylvania federal judge on Tuesday to toss a case alleging it delayed the introduction of a competitor to Suboxone, saying the 35 states that brought the suit failed to allege how a new formula of the original drug prevented generics from succeeding in the market.
December 13, 2016
Indivior Inc. asked a Pennsylvania federal court Monday to ax claims brought by more than 40 states that allege the company unlawfully stifled generic competition for opiate addiction treatment Suboxone, saying circuit courts have dismissed similar product-hopping allegations.
November 18, 2016
Six states on Thursday joined an antitrust suit against Indivior in Pennsylvania federal court, alleging that the British drugmaker is unlawfully attempting to keep a generic version of opiate addiction treatment Suboxone off the market.